MHE February 2024

Christopher Starr, M.D., of Weill Cornell Medical College in New York discusses of the challenges of making a diagnosis and a new treatment.

How health plans and self-insured employers coped with the huge number of prescriptions for weight loss. It started with off-label Ozempic (semaglutide) and now there’s FDA-approved Wegovy (semaglutide) and Zepbound (tirzepatide).